Eris Lifesciences stated that its consolidated net profit increased 12 per cent to Rs 101 crore for the third quarter ended December 2021.
The company stated that the revenue stood at Rs 332 crore in the third quarter of the current fiscal as against Rs 310 crore in the year-ago period, Eris Lifesciences said.
''Our focus on building leadership brands in fast-growing therapies coupled with several patent expiration opportunities will enable us to sustain our growth trajectory,'' stated Eris Lifesciences Chairman & Managing Director Amit Bakshi.
(With inputs from PTI)
BMC Election 2026 Rebel & Withdrawn Candidates
Animal Groups Accuse Civic Bodies Of Selective Supreme Court Compliance Ahead Of ‘Do Or Die’ Protest
Mumbai News: HDIL Homebuyers Protest At Azad Maidan After 17 Years Of Waiting For Stalled Mulund, Nahur Projects
Mumbai News: SHRC Raps Govt Over 139 Vacant Medical Posts In Civic Hospitals, Orders Inquiry Over Public Health Concerns
